A Study to Investigate the Efficacy and Safety of Lusutrombopag (S-888711) Tablets Administered to Adults With Immune Thrombocytopenia (ITP)

Immune Thrombocytopenia (ITP) Clinical Trial

Official title:
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of S-888711 Tablets Administered Once-daily for 42 Days to Adult Subjects With Relapsed Persistent or Chronic Immune Thrombocytopenia With or Without Prior Splenectomy

Status Terminated

Clinical Trial Summary

The primary objective of this study was to assess the efficacy of 3 dose levels of lusutrombopag (0.5 mg, 0.75 mg, and 1.0 mg) and placebo on platelet count.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Immune Thrombocytopenia (ITP)
Purpura, Thrombocytopenic, Idiopathic
Thrombocytopenia

Clinical Trial Details

NCT number	NCT01054443
Study type	Interventional
Source	Shionogi Inc.
Contact
Status	Terminated
Phase	Phase 2
Start date	March 18, 2010
Completion date	November 24, 2010

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02868060` - Evaluating the Pharmacokinetics and Pharmacodynamics of Romiplostim in Patients With Immune Thrombocytopenia (ITP)	Phase 1/Phase 2
Completed	`NCT04346654` - A Study to Assess Efficacy and Safety of Eltrombopag in Combination With a Short Course of Dexamethasone in Patients With Newly Diagnosed ITP	Phase 2
Not yet recruiting	`NCT06371417` - Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)	Phase 1
Recruiting	`NCT04915482` - TPO-RAs Combined With Anti-CD20 Antibody in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies	Phase 2/Phase 3
Completed	`NCT00344149` - Rituximab as Second Line Treatment for ITP	Phase 3
Completed	`NCT04669600` - A Phase 2a Study Evaluating BIVV020 in Adults With Persistent/Chronic Immune Thrombocytopenia (ITP)	Phase 2
Completed	`NCT01666795` - Autoantibody Specificity and Response to IVIG in ITP	N/A
Active, not recruiting	`NCT05086744` - Basket Study to Assess Efficacy, Safety and PK of Iptacopan (LNP023) in Autoimmune Benign Hematological Disorders	Phase 2
Recruiting	`NCT03951623` - The Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-523 in Immune Thrombocytopenia Patients	Phase 1
Recruiting	`NCT04968899` - IgIV Plus Prednisone vs High-dose Dexamethasone for ITP	Phase 3
Recruiting	`NCT03975361` - Autoreactivity Threshold Analysis in Lupus and Immune Thrombocytopenia (Checkpoints ITP and SLE)	N/A